Sen. Bill Cassidy (R-LA) argued Wednesday (Dec. 7) that making patients pay more for innovator biologics would increase uptake in biosimilars, while also maintaining that his office is exploring ways to address drug pricing in the upcoming user fee authorizations. Uptake and availability of biosimilars, which many have seen as a way to address the high cost of biologic medicines, was a focus of key lawmakers during a Wednesday policy briefing on biosimilars hosted by The Atlantic . Cassidy cited...